"Myositis, Inclusion Body" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)
| Descriptor ID |
D018979
|
| MeSH Number(s) |
C05.651.594.600 C10.668.491.562.500
|
| Concept/Terms |
Myositis, Inclusion Body- Myositis, Inclusion Body
- Inclusion Body Myositides
- Myositides, Inclusion Body
- Inclusion Body Myositis
Inclusion Body Myopathy, Sporadic- Inclusion Body Myopathy, Sporadic
- Myositis, Inclusion Body, Sporadic
- Myopathy, Inclusion Body, Sporadic
- Inclusion Body Myositis, Sporadic
- Sporadic Inclusion Body Myositis
|
Below are MeSH descriptors whose meaning is more general than "Myositis, Inclusion Body".
Below are MeSH descriptors whose meaning is more specific than "Myositis, Inclusion Body".
This graph shows the total number of publications written about "Myositis, Inclusion Body" by people in this website by year, and whether "Myositis, Inclusion Body" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myositis, Inclusion Body" by people in Profiles.
-
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
-
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
-
Spinal Cord and Motor Neuron TDP-43 Pathology in a Sporadic Inclusion Body Myositis Patient. J Neuropathol Exp Neurol. 2020 10 01; 79(10):1130-1133.
-
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 09; 18(9):834-844.
-
Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis Rheumatol. 2017 05; 69(5):1090-1099.
-
Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016 03 03; 3(1):67-75.
-
Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013 Mar; 73(3):408-18.
-
Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a Drosophila IBMPFD model. PLoS Genet. 2011 Feb 03; 7(2):e1001288.
-
Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol. 2009 Dec 14; 187(6):875-88.